KRAS and colorectal carcinoma: Since tumor microenvironment modulates the responsiveness to drugs in vivo, we examined the growth inhibition potential of Mit-A in ex vivo MC-38 (murine CRC cells, p53 mutant, K-RAS wild-type, microsatellite instable)23 and HT-29 tumoroid growth.